{"title":"The Antinociceptive Effects of Combined Treatment With Atorvastatin and Vitamin C in the Chronic Constriction Injury Model of Rats.","authors":"Abolfazl Abbaszadeh, Najmeh Pirzadroozbahani, Mahmood Reza Moradkhani, Amin Hasanvand","doi":"10.32598/bcn.2022.895.2","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Neuropathic pain (NP) is caused by damage to the somatosensory system. Nerve damage often results in chronic pain states, including hyperalgesia and allodynia. This study aims to evaluate the anti-nociceptive effects of atorvastatin, vitamin C, and their combination on various laboratory tests in an experimental model NP in rats.</p><p><strong>Methods: </strong>To assess the analgesic effects of atorvastatin (5 and 10 mg/kg), vitamin C (500 mg/kg), and their co-administration on chronic constriction injury (CCI) was induced in rats. Behavioral tests, motor nerve conduction velocity (MNCV), pro-inflammatory cytokines, and oxidative markers were measured. Furthermore, histopathological examination was performed.</p><p><strong>Results: </strong>In the present study, it was found that the CCI model can significantly cause hyperalgesia and allodynia on the 21<sup>st</sup> postoperative day. It was found that the co-administration of vitamin C and atorvastatin has attenuating effects on allodynia and hyperalgesia. Co-administration of vitamin C and atorvastatin also improved MNCV. In the treatment groups, the inflammatory reactions and oxidative markers decreased. Moreover, the co-administration of atorvastatin and vitamin C decreased the perineural inflammation around the sciatic nerve.</p><p><strong>Conclusion: </strong>The results of this study showed that vitamin C potentiates the analgesic effects of atorvastatin in this model of experimental pain, and simultaneous consumption of these medications may be considered as effective therapeutics for NP. The protective properties of atorvastatin, and vitamin C, and their combination on the NP that were assessed can be regarded as a novelty for this study.</p><p><strong>Highlights: </strong>The co-administration of atorvastatin and vitamin C significantly decreases inflammatory cytokines.The co-administration of atorvastatin and vitamin C significantly decreases stress oxidant markers.The co-administration of atorvastatin and vitamin C significantly attenuated nociceptive effects.</p><p><strong>Plain language summary: </strong>Nerve damage causes the deposition of inflammatory factors and or oxidative stress at the site of injury, which in turn activates glial cells that are involved in increasing the inflammatory process by producing and releasing pro-inflammatory agents and oxidative stress. Among statins, atorvastatin is a drug to reduce inflammation, and its effectiveness has been recorded as an antioxidant effect. Vitamin C is known as a neuroprotective agent. Ascorbate inhibits the production of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in monocytes in high doses (20 mM) by inhibiting them. The rats were randomly divided into 7 groups of 10 animals as follows: 1: Sham-operated, 2: Chronic constriction injury (CCI), 3: CCI+vitamin C (500 mg/kg), 4: CCI+atorvastatin (5 mg/kg), 5: CCI+atorvastatin (10 mg/kg), 6: CCI+vitamin C (500 mg/kg)+atorvastatin (5 mg/kg), and 7: CCI+vitamin C (500 mg/kg)+atorvastatin (10 mg/kg). The results of the present study indicated that the anti-inflammatory, antioxidant, and neuroprotective properties of vitamin C and atorvastatin improved the effects of CCI in an empirical neuropathic in rats. Moreover, it was shown that the associated treatment with vitamin C and atorvastatin can reduce inflammatory factors, such as TNF-α and IL-6, and oxidative markers, such as glutathione peroxidase (GPx), superoxide dismutase (SOD), and malonaldehyde (MDA), while the nerve conduction velocity enhanced and inflammation decreased in histology studies in CCI rats.</p>","PeriodicalId":8701,"journal":{"name":"Basic and Clinical Neuroscience","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11273201/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Basic and Clinical Neuroscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32598/bcn.2022.895.2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: Neuropathic pain (NP) is caused by damage to the somatosensory system. Nerve damage often results in chronic pain states, including hyperalgesia and allodynia. This study aims to evaluate the anti-nociceptive effects of atorvastatin, vitamin C, and their combination on various laboratory tests in an experimental model NP in rats.
Methods: To assess the analgesic effects of atorvastatin (5 and 10 mg/kg), vitamin C (500 mg/kg), and their co-administration on chronic constriction injury (CCI) was induced in rats. Behavioral tests, motor nerve conduction velocity (MNCV), pro-inflammatory cytokines, and oxidative markers were measured. Furthermore, histopathological examination was performed.
Results: In the present study, it was found that the CCI model can significantly cause hyperalgesia and allodynia on the 21st postoperative day. It was found that the co-administration of vitamin C and atorvastatin has attenuating effects on allodynia and hyperalgesia. Co-administration of vitamin C and atorvastatin also improved MNCV. In the treatment groups, the inflammatory reactions and oxidative markers decreased. Moreover, the co-administration of atorvastatin and vitamin C decreased the perineural inflammation around the sciatic nerve.
Conclusion: The results of this study showed that vitamin C potentiates the analgesic effects of atorvastatin in this model of experimental pain, and simultaneous consumption of these medications may be considered as effective therapeutics for NP. The protective properties of atorvastatin, and vitamin C, and their combination on the NP that were assessed can be regarded as a novelty for this study.
Highlights: The co-administration of atorvastatin and vitamin C significantly decreases inflammatory cytokines.The co-administration of atorvastatin and vitamin C significantly decreases stress oxidant markers.The co-administration of atorvastatin and vitamin C significantly attenuated nociceptive effects.
Plain language summary: Nerve damage causes the deposition of inflammatory factors and or oxidative stress at the site of injury, which in turn activates glial cells that are involved in increasing the inflammatory process by producing and releasing pro-inflammatory agents and oxidative stress. Among statins, atorvastatin is a drug to reduce inflammation, and its effectiveness has been recorded as an antioxidant effect. Vitamin C is known as a neuroprotective agent. Ascorbate inhibits the production of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in monocytes in high doses (20 mM) by inhibiting them. The rats were randomly divided into 7 groups of 10 animals as follows: 1: Sham-operated, 2: Chronic constriction injury (CCI), 3: CCI+vitamin C (500 mg/kg), 4: CCI+atorvastatin (5 mg/kg), 5: CCI+atorvastatin (10 mg/kg), 6: CCI+vitamin C (500 mg/kg)+atorvastatin (5 mg/kg), and 7: CCI+vitamin C (500 mg/kg)+atorvastatin (10 mg/kg). The results of the present study indicated that the anti-inflammatory, antioxidant, and neuroprotective properties of vitamin C and atorvastatin improved the effects of CCI in an empirical neuropathic in rats. Moreover, it was shown that the associated treatment with vitamin C and atorvastatin can reduce inflammatory factors, such as TNF-α and IL-6, and oxidative markers, such as glutathione peroxidase (GPx), superoxide dismutase (SOD), and malonaldehyde (MDA), while the nerve conduction velocity enhanced and inflammation decreased in histology studies in CCI rats.
简介神经性疼痛(NP)是由躯体感觉系统受损引起的。神经损伤通常会导致慢性疼痛状态,包括痛觉减退和异动症。本研究旨在评估阿托伐他汀、维生素 C 及其复方制剂在大鼠神经病理性疼痛实验模型的各种实验室测试中的抗痛觉效应:评估阿托伐他汀(5 毫克和 10 毫克/千克)、维生素 C(500 毫克/千克)及其联合用药对大鼠慢性收缩性损伤(CCI)的镇痛作用。对大鼠的行为测试、运动神经传导速度(MNCV)、促炎细胞因子和氧化标记物进行了测定。此外,还进行了组织病理学检查:本研究发现,CCI 模型可在术后第 21 天显著引起痛觉减退和异动症。同时服用维生素 C 和阿托伐他汀可减轻异感和痛觉减退。同时服用维生素 C 和阿托伐他汀还能改善 MNCV。在治疗组中,炎症反应和氧化标记物均有所下降。此外,同时服用阿托伐他汀和维生素 C 可减少坐骨神经周围的神经炎症:本研究结果表明,在这种实验性疼痛模型中,维生素 C 可增强阿托伐他汀的镇痛效果,同时服用这两种药物可被视为治疗 NP 的有效疗法。阿托伐他汀和维生素 C 的保护特性以及它们的组合对 NP 的评估可以说是这项研究的一个新亮点:联合应用阿托伐他汀和维生素 C 能显著降低炎性细胞因子。联合应用阿托伐他汀和维生素 C 能显著降低应激氧化标记物。白话摘要:神经损伤会导致炎症因子和氧化应激在损伤部位沉积,进而激活神经胶质细胞,神经胶质细胞通过产生和释放促炎因子和氧化应激,参与加剧炎症过程。在他汀类药物中,阿托伐他汀是一种减少炎症的药物,其抗氧化效果已被记录在案。维生素 C 是众所周知的神经保护剂。高剂量(20 mM)抗坏血酸可抑制单核细胞产生白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)。将大鼠随机分为以下 7 组,每组 10 只:1: Sham-operated;2: Chronic constriction injury (CCI);3: CCI+vitamin C (500mg/kg);4: CCI+atorvastatin (5mg/kg);5: CCI+atorvastatin (10mg/kg);6: CCI+vitamin C (500mg/kg)+atorvastatin (5mg/kg);7: CCI+vitamin C (500mg/kg)+atorvastatin (10mg/kg)。本研究结果表明,维生素 C 和阿托伐他汀的抗炎、抗氧化和神经保护特性改善了 CCI 对经验性神经病理性大鼠的影响。此外,研究还表明,维生素 C 和阿托伐他汀的联合治疗可降低 TNF-α 和 IL-6 等炎症因子以及谷胱甘肽过氧化物酶 (GPx)、超氧化物歧化酶 (SOD) 和丙二醛 (MDA) 等氧化标志物,而在组织学研究中,CCI 大鼠的神经传导速度提高,炎症减轻。
期刊介绍:
BCN is an international multidisciplinary journal that publishes editorials, original full-length research articles, short communications, reviews, methodological papers, commentaries, perspectives and “news and reports” in the broad fields of developmental, molecular, cellular, system, computational, behavioral, cognitive, and clinical neuroscience. No area in the neural related sciences is excluded from consideration, although priority is given to studies that provide applied insights into the functioning of the nervous system. BCN aims to advance our understanding of organization and function of the nervous system in health and disease, thereby improving the diagnosis and treatment of neural-related disorders. Manuscripts submitted to BCN should describe novel results generated by experiments that were guided by clearly defined aims or hypotheses. BCN aims to provide serious ties in interdisciplinary communication, accessibility to a broad readership inside Iran and the region and also in all other international academic sites, effective peer review process, and independence from all possible non-scientific interests. BCN also tries to empower national, regional and international collaborative networks in the field of neuroscience in Iran, Middle East, Central Asia and North Africa and to be the voice of the Iranian and regional neuroscience community in the world of neuroscientists. In this way, the journal encourages submission of editorials, review papers, commentaries, methodological notes and perspectives that address this scope.